Khiron Life Sciences (KHRN.V), one of the first medical marijuana companies to be fully-licensed in Colombia, isn’t concerning itself with the Californian cannabis market.

Instead, the company has set its sights on legalized regions outside the U.S. like Latin America and Europe. These markets may not be as big as California and the U.S., but they are sizable, sustainable and more than available in the nascent multi-billion-dollar global weed marketplace.

Equity.Guru’s Chris Parry spoke with Khiron president, Chris Naprawa, to get a bird’s eye view of the company, the international legal cannabis market, the 2018 farm bill and what the capital markets can expect from Khiron over the next 12 months.


Listen in!

Check out our Podbean site and iTunes channel for more great content!

Written By:

Chris Parry

A multi-Webster Award winner for excellence in BC journalism, Parry is the founder and publisher of Equity.Guru, which he built with the specific plan to blend old school reporting with stock promotion, in a way that puts the emphasis on truth, high standards, and ethics. Parry is a veteran of TV, radio, and print, and consults with public companies to help them figure out their storylines, lay down achievable milestones, and improve their communication with shareholders, while also posting regular deep dive analysis of companies in the public spotlight.

More By This Author